Biotech | April 06, 2022
Alvotech and STADA pave way to launching Hukyndra
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The new facility is scheduled to start operation in the first half of 2024
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Supply increase to help meet growing global demand
The fund has already invested in seven companies including Medikabazaar, THB, Impact Guru, Stanplus, Ekincare, Qure.ai and HealthifyMe
Dupixent peak sales ambition raised to more than €13 billion
Aquavit will officially unveil the Dermatox and Microtox programs at the Annual American Academy of Dermatology, the world's largest dermatology conference scheduled from March 25-29, 2022, in Boston, MA
This announcement comes after the formation of a new Intercontinental Region within GE Healthcare, led by Chaillot
According to IQVIA sales data for the period ending January 2022, Vimpat tablets market achieved annual sales of approx. US $ 1.7 billion
The company plans to launch the product immediately
Subscribe To Our Newsletter & Stay Updated
